Verapamil (oral)

Verapamil is an old, inexpensive blood-pressure and heart-rhythm pill that turned out to do something unexpected in T1D: started around the time of diagnosis, it helps the surviving insulin-producing cells last longer, preserving more of the body's own insulin. It does not prevent or delay the disease — it tries to protect what remains at the moment of new-onset (stage 3) diagnosis.

Where verapamil fits: screening and staging

T1D develops in stages that can be detected years before symptoms. Stage 1 is two or more islet autoantibodies with normal glucose; stage 2 adds abnormal glucose; stage 3 is clinical diabetes needing insulin.⁷ Screening a blood sample for these autoantibodies identifies who is on this path — and finding people early sharply reduces the chance of presenting in diabetic ketoacidosis (DKA), a dangerous emergency: general-population screening programmes have been reported to cut DKA at diagnosis more than tenfold.⁸ Confirmed multiple-autoantibody positivity carries a very high lifetime risk of progression, and consensus guidance covers monitoring of such individuals.⁷ Verapamil, importantly, is not a screening-stage drug: its evidence is entirely at new-onset, after diagnosis. It complements early detection rather than acting on it.

The therapy: mechanism and effect

In the lab, verapamil lowers a stress protein (TXNIP) that drives insulin-producing-cell death, and it nudges human islets toward an anti-inflammatory, survival-favouring state.² In the first human trial — 26 adults with recent-onset T1D given sustained-release verapamil — stimulated C-peptide (the standard marker of the body's own insulin output) was significantly better preserved than placebo at both 3 and 12 months, with a between-group difference of about 0.28 nmol/L at 12 months.¹ A larger follow-up showed the benefit persisted for at least two years with continued daily use, alongside lower insulin needs — but the effect was lost when people stopped, so it suppresses rather than cures.²

The strongest evidence is in children. The CLVer trial (NCT04233034, 88 newly diagnosed 7–17-year-olds) found verapamil partially preserved C-peptide at 52 weeks — roughly 30% higher than placebo (between-group difference 0.14 pmol/mL, P=0.04) — with 95% of the verapamil group versus 71% on placebo still making meaningful insulin.³

Safety is reassuring given decades of cardiovascular use: the main issue is constipation, with dose-dependent slowing of the heart (bradycardia, first-degree AV block) that needs an occasional ECG check.⁹ No approval exists for T1D, so it is used off-label; the drug itself is generic and oral.¹

What's coming

The honest 2025 headline is mixed. Ver-A-T1D — the largest adult trial (136 adults, 21 sites across six European countries, 360 mg/day) — narrowly missed statistical significance for its primary C-peptide endpoint, showing only a non-significant trend.⁹ Verapamil was again safe (first-degree AV block ~22%, bradycardia ~16%, both manageable).⁹ The takeaway from the field is that verapamil's effect is real but small, and its future most likely lies combined with immune-modulating disease-modifying therapies rather than alone — with longer follow-up and combination trials now the priority.⁹

That thesis is now actually being tested. WAVE T1D (NCT07061574), run by City of Hope with the Jaeb Center, has been recruiting since March 2026: 120 young people aged 9 to under 21, randomised within six months of diagnosis, receive a short course of low-dose anti-thymocyte globulin (ATG, an immune therapy) and are then assigned to follow-on treatment with adalimumab, verapamil, or placebo — the ATG-plus-placebo arm is what makes the comparison meaningful — with stimulated C-peptide measured at two years.⁶ It asks verapamil's most important remaining question directly — not "does the pill work on its own?", to which we now have a reasonably honest answer, but "does it add anything on top of an immune therapy?"